Plexium
Plexium, Inc.
Plexium, Inc. is a clinical-stage biotechnology company focused on developing a new generation of targeted protein degradation (TPD) therapies. The company utilizes its proprietary discovery platform to engineer novel small molecules, such as molecular glues and monovalent degraders, to eliminate previously "undruggable" proteins associated with cancer and other serious diseases.
Products & Team
Proprietary Drug Discovery Platform
Plexium's core offering is its integrated drug discovery platform designed to identify and advance next-generation targeted protein degraders. The platform is engineered to screen vast libraries of small molecules to find those that can induce the degradation of specific disease-causing proteins through the body's natural E3 ligase pathway, effectively treating diseases at their source.
The platform solves the significant challenge of drugging conventionally "undruggable" proteins, which are often implicated in severe diseases like cancer and neurodegenerative disorders. It offers a new modality for therapeutic intervention where traditional inhibitors have failed.
Plexium addresses the critical need within the pharmaceutical industry to find effective treatments for diseases driven by proteins that cannot be targeted by conventional small molecule inhibitors or other therapeutic approaches.